Clinical Trial Update: Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD

View source ↗

Summary

A clinical trial update indicating a recruiting study for colorectal cancer evaluating Delta-HLD by Epiliquid Holding, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: Epiliquid Holding, Inc | Conditions: Colo-rectal Cancer | Status: RECRUITING